NCT07502768 2026-03-31
EpiRev-NKT
Fudan University
Phase 1/2 Not yet recruiting
Clinical Trials
9 trialsNCT07457177 2026-03-09
Phaes â…¡ Study of Golidocitinib-Pegaspargase-PD-1 Antibody First-Line for Advanced ENKTL
Beijing Tongren Hospital
Phase 2 Not yet recruiting
NCT07385989 2026-02-04
Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed Advanced or Non-Nasal Extranodal NK/T-Cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting
NCT07276698 2025-12-11
Clinical Study on Maintenance Therapy With Selinexor Combined With Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for NK/T-cell Lymphoma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Not yet recruiting
NCT07276737 2025-12-11
Preconditioning With a Combination of Thiotepa, Cyclophosphamide, and Busulfan for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of NK/T-Cell Lymphoma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Not yet recruiting
NCT06953739 2025-05-01
A Study Comparing of P-GEMD Regimen Versus P-Gemox Regimen With Untreated Early-Stage NUAT or Advanced-Stage ENKTL.
The First Affiliated Hospital with Nanjing Medical University
Phase 3 Not yet recruiting
NCT06863441 2025-03-07
The Value of PET Imaging Targeting Granzyme B in Predicting Efficacy and Prognosis in T-NK Cell Lymphoma
Ruijin Hospital
Not yet recruiting
NCT06747299 2024-12-24
The Value of Artificial Intelligence-based 18F-FDG PET/CT in Diferential Diagnosis, Efficacy Prediction and Prognosis Prediction of T-NK Cell Lymphoma: a Clinical Study
Ruijin Hospital
Not yet recruiting
NCT06573138 2024-08-27
Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL
Ruijin Hospital
Phase 2 Not yet recruiting